RESEARCH-USE BIOSIMILAR ANTIBODY

Dinutuximab

Monoclonal antibody · IgG1

Ganglioside GD2IgG1RUO

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer.

TARGETGanglioside GD2
YMonoclonal antibody
CATALOGSC-BS-624
CATALOG NUMBERSC-BS-624
MOLECULAR WEIGHTApprox. 145.012 kDa
PRODUCT FORMATMonoclonal antibody

A research-use configuration for comparative antibody studies

Dinutuximab (APN-311) is a chimeric human-mouse anti-GD2 monoclonal antibody. Dinutuximab can bind to GD2 on the cell surface, triggering antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, and promoting tumor regression. Dinutuximab can inhibit the growth, invasion, and migration and induce apoptosis of tumor cells. Dinutuximab can be used in the research of tumors such as neuroblastoma and breast cancer.

Dinutuximab is a recombinant research-use antibody directed against Ganglioside GD2.

START A CONVERSATION

Tell us about your research goals.

For quotes, sample requests or technical support, start with your target and experimental context.

Contact StellaCyte
Dinutuximab | StellaCyte